FDA panel rejects Sunrise eye laser after concerns that benefits of treatment wear off
This article was originally published in Clinica
Executive Summary
Advisors to the US FDA last week recommended that an application by Sunrise Technologies for approval of its LTK laser for treating low to moderate farsightedness be rejected. The panel was concerned that the initial improvement in the vision of these patients seemed to wear off two years later.